コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
2 For similar levels of urate lowering, the uricosuric agent probenecid had no effect on endothelial
3 erging therapies, including pegloticase, the uricosuric agent RDEA596, and the interleukin-1 inhibito
4 tablished that benzbromarone (BBR), a potent uricosuric agent used in the management of gout, irrever
9 f diuretics, beta-blockers, allopurinol, and uricosuric agents, self-reported hypertension and gout,
14 by off-target inhibition, for example by the uricosuric drug probenecid, elevates circulating bilirub
15 peline drugs for gout, such as the selective uricosuric drug RDEA594 and various interleukin-1 inhibi
16 -phenylbutyrate and probenecid, the latter a uricosuric drug used clinically to treat gout, markedly
17 rate uptake was inhibited in the presence of uricosuric drugs, specific inhibitors of protein tyrosin
19 tency of 10 drugs in five different classes (uricosuric, nonsteroidal anti-inflammatories, loop diure
20 the impact of xanthine oxidase inhibitors or uricosurics on clinical hypertension and chronic kidney
21 st antihypertensive drugs in possessing mild uricosuric properties and therefore has a role in treati